How have ABVC shares performed in 2024?

ABVC BioPharma's stock was trading at $1.16 at the beginning of 2024. Since then, ABVC shares have decreased by 15.5% and is now trading at $0.9802. View the best growth stocks for 2024 here .

Are investors shorting ABVC BioPharma?

ABVC BioPharma saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,320,000 shares, an increase of 1,146.5% from the March 15th total of 105,900 shares. Based on an average daily volume of 706,600 shares, the days-to-cover ratio is currently 1.9 days. Currently, 15.2% of the company's shares are sold short. View ABVC BioPharma's Short Interest .

When is ABVC BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ABVC earnings forecast .

How were ABVC BioPharma's earnings last quarter?

ABVC BioPharma, Inc. (NASDAQ:ABVC) posted its quarterly earnings results on Wednesday, March, 13th. The company reported ($0.35) earnings per share for the quarter. ABVC BioPharma had a negative net margin of 6,919.08% and a negative trailing twelve-month return on equity of 226.65%.

When did ABVC BioPharma's stock split?

Shares of ABVC BioPharma reverse split on Tuesday, July 25th 2023. The 1-10 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did ABVC BioPharma IPO?

ABVC BioPharma (ABVC) raised $7 million in an initial public offering on Tuesday, August 3rd 2021. The company issued 1,100,000 shares at a price of $6.25 per share.

How do I buy shares of ABVC BioPharma?

Shares of ABVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ABVC

ABVC BioPharma (ABVC) Stock Price, News & Analysis

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Free ABVC Stock Alerts

$0.98

-0.04 (-3.90%)

(As of 01:32 PM ET)

Compare

Today's Range: $0.94
▼
$1.08
50-Day Range: $1.02
▼
$1.37
52-Week Range: $0.67
▼
$9.60

Volume: 390,433 shs
Average Volume: 1.97 million shs
Market Capitalization: $10.35 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get ABVC BioPharma alerts:

Ad InvestorPlace

The #1 Crypto for 2024

5 Tiny Cryptos That Could Soar During 2024 Crypto Bull Run One of the first ever crypto millionaires who bought Bitcoin when it was trading for just $5 in 2011 is back with his next huge prediction. A newly approved government regulation is set to flood trillions of dollars into the crypto markets, leading to the FINAL crypto bull run. One of the "Kings of Crypto" has revealed five tiny cryptos that could soar over the course of 2024. Potentially resulting in gains as big as 10X, 50X, or even 100X over the next 12 months.

Get His #1 Coin For 2024 FREE By Clicking Here

About ABVC BioPharma Stock (NASDAQ:ABVC)

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

ABVC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ABVC Stock News Headlines

April 18, 2024 | finanznachrichten.de

ABVC BioPharma, Inc.: AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share

April 18, 2024 | globenewswire.com

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share

April 18, 2024 | InvestorPlace (Ad)

The #1 Crypto for 2024

April 17, 2024 | markets.businessinsider.com

ABVC BioPharma Enters Licensing Agreement With OncoX For Commercialization Of BLEX 404

April 17, 2024 | finance.yahoo.com

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

April 17, 2024 | globenewswire.com

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

April 11, 2024 | americanbankingnews.com

Short Interest in ABVC BioPharma, Inc. (NASDAQ:ABVC) Expands By 1,146.5%

April 10, 2024 | globenewswire.com

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

April 18, 2024 | InvestorPlace (Ad)

The #1 Crypto for 2024

March 28, 2024 | finanznachrichten.de

ABVC BioPharma, Inc.: ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M

March 27, 2024 | msn.com

Why ABVC BioPharma Stock Is Up Today

March 26, 2024 | markets.businessinsider.com

ABVC Announces Global Licensing Deal With ForSeeCon Eye For Vitargus

March 26, 2024 | globenewswire.com

ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M

March 21, 2024 | finance.yahoo.com

AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars

March 19, 2024 | ca.finance.yahoo.com

ABVC BioPharma, Inc. (ABVC) Interactive Stock Chart - Yahoo Finance

March 19, 2024 | globenewswire.com

ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine

March 14, 2024 | finanznachrichten.de

ABVC BioPharma, Inc.: ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

March 14, 2024 | globenewswire.com

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

February 27, 2024 | finance.yahoo.com

ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars

February 15, 2024 | finanznachrichten.de

ABVC BioPharma, Inc.: ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues

February 15, 2024 | markets.businessinsider.com

ABVC Signes Agreement To License Its 'Know-How' To SPI

February 15, 2024 | finance.yahoo.com

ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues

February 15, 2024 | globenewswire.com

ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues

February 12, 2024 | finanznachrichten.de

ABVC BioPharma, Inc.: ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)

February 12, 2024 | markets.businessinsider.com

ABVC BioPharma Receives Australian Patent For PDC-1421 For Treatment Of MDD

February 12, 2024 | finance.yahoo.com

ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)

February 9, 2024 | msn.com

ABVC BioPharma Conducts Private Equity and Warrants Sale

See More Headlines

Receive ABVC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ABVC BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/13/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ABVC
CUSIP: N/A
CIK: 1173313
Web: www.abvcpharma.com
Phone: (510)-668-0881
Fax: N/A
Employees: 16
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.45)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,520,000.00
Net Margins: -6,919.08%
Pretax Margin: -6,989.44%
Return on Equity: -226.65%
Return on Assets: -82.26%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.28
Quick Ratio: 0.28

Sales & Book Value

Annual Sales: $150,000.00
Price / Sales: 71.81
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.02 per share
Price / Book: 1.00

Miscellaneous

Outstanding Shares: 10,560,000
Free Float: 9,303,000
Market Cap: $10.77 million
Optionable: Not Optionable
Beta: 0.75

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Eugene Jiang (Age 38)
Chairman & Chief Business Officer
Comp: $200k
Dr. Uttam Yashwant Patil Ph.D. (Age 38)
Chief Executive Officer
Mr. Leeds Chow (Age 34)
CFO & Principal Accounting Officer
Comp: $180k
Dr. Tsung-Shann Jiang EMBA (Age 70)
Ph.D., Chief Scientific Officer, Chief Strategy Officer & Director
Comp: $200k

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ABVC Stock Analysis - Frequently Asked Questions

How have ABVC shares performed in 2024?: ABVC BioPharma's stock was trading at $1.16 at the beginning of 2024. Since then, ABVC shares have decreased by 15.5% and is now trading at $0.9802.
View the best growth stocks for 2024 here.
Are investors shorting ABVC BioPharma?: ABVC BioPharma saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,320,000 shares, an increase of 1,146.5% from the March 15th total of 105,900 shares. Based on an average daily volume of 706,600 shares, the days-to-cover ratio is currently 1.9 days. Currently, 15.2% of the company's shares are sold short.
View ABVC BioPharma's Short Interest.
When is ABVC BioPharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ABVC earnings forecast.
How were ABVC BioPharma's earnings last quarter?: ABVC BioPharma, Inc. (NASDAQ:ABVC) posted its quarterly earnings results on Wednesday, March, 13th. The company reported ($0.35) earnings per share for the quarter. ABVC BioPharma had a negative net margin of 6,919.08% and a negative trailing twelve-month return on equity of 226.65%.

When did ABVC BioPharma's stock split?: Shares of ABVC BioPharma reverse split on Tuesday, July 25th 2023. The 1-10 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
When did ABVC BioPharma IPO?: ABVC BioPharma (ABVC) raised $7 million in an initial public offering on Tuesday, August 3rd 2021. The company issued 1,100,000 shares at a price of $6.25 per share.
How do I buy shares of ABVC BioPharma?: Shares of ABVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ABVC) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ABVC BioPharma (ABVC) Stock Price, News & Analysis

About ABVC BioPharma Stock (NASDAQ:ABVC)

ABVC Stock Price History

ABVC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

ABVC Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info